<DOC>
	<DOCNO>NCT01352650</DOCNO>
	<brief_summary>The hypothesis proposal combine plerixafor , inhibitor stromal cell derive factor - 1α ( SDF-1α ) , decitabine , DNA methyltransferase inhibitor , induction postremission therapy old patient Acute Myeloid Leukemia ( AML ) improve treatment outcome via mobilization leukemia stem cell alteration pharmacodynamics decitabine . The protocol establish safety feasibility combine two different dos plerixafor fix dose schedule decitabine .</brief_summary>
	<brief_title>Decitabine Plerixafor Elderly Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Unequivocal pathologic diagnosis AML ( ≥ 20 % blast bone marrow base WHO criterion ) exclude : ) acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA ; ii ) acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 ) ; RUNX1RUNXT1 ; iii ) acute myeloid leukemia inv ( 16 ) ( p13.1 ; q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; CBFBMYH11 . AML patient antecedent hematologic disorder myelodysplastic syndrome ( MDS ) eligible treatment trial provide received prior treatment decitabine prior cytotoxic treatment AML . AML patient therapyrelated myeloid neoplasm ( tMN ) eligible receive chemotherapy ( include hormonal therapy ) primary malignancy disorder &gt; 6 month . Age ≥ 60 year . Ability understand willingness sign write informed consent document . Prior treatment decitabine Prior treatment plerixafor Ongoing treatment another malignancy . Patients goodrisk molecular cytogenetics feature Patient medical condition illness consider investigator constitute unwarranted high risk investigational drug treatment . Patient psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study . Patient inability unwillingness , opinion investigator , comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leukemia</keyword>
</DOC>